>>Signaling Pathways>> Neuroscience>> Behavioral Neuroscience>>(±)-Nicotine-d3

(±)-Nicotine-d3 (Synonyms: DL-Nicotine-d3, (±)-Nicotine-methyl-d3)

Catalog No.GC46305

An internal standard for the quantification of (±)-nicotine

Products are for research use only. Not for human use. We do not sell to patients.

(±)-Nicotine-d3 Chemical Structure

Cas No.: 69980-24-1

Size 가격 재고 수량
5 mg
US$77.00
재고 있음
10 mg
US$147.00
재고 있음
25 mg
US$348.00
재고 있음
50 mg
US$616.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

(±)-Nicotine-d3 is intended for use as an internal standard for the quantification of (±)-nicotine by GC- or LC-mass spectrometry. (±)-Nicotine is the racemic mixture of the dominant alkaloid found in tobacco plants. It acts as an agonist at neuronal nicotinic acetylcholine receptors (nAChRs; Kis = 481 and 11.1 nM for α3β4 and α4β2 subtypes, respectively) and possesses addictive and teratogenic properties.1 (-)-(S)-Nicotine is significantly more active at binding nAChRs compared to the (+)-(R) antipode, thus nicotine is typically synthesized as (-)-(S)-nicotine with only 0.2-1% of the (+)-(R) isomer present.2

1.Zaveri, N., Jiang, F., Olsen, C., et al.Novel α3β4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluationJ. Med. Chem.53(22)8187-8191(2010) 2.Clayton, P., Lu, A., and Bishop, L.The pyrolysis of (-)-(S)-nicotine: Racemization and decompositionChirality22(4)442-446(2010)

리뷰

Review for (±)-Nicotine-d3

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (±)-Nicotine-d3

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.